Utility of Interferon-γ Release Assay Results to Monitor Anti-tubercular Treatment in Adults and Children
Overview
Authors
Affiliations
Background: Interferon-γ release assays (IGRAs), including the commercially available T-SPOT.TB, QuantiFERON-TB Gold (QFT-G), and QuantiFERON-TB Gold In-Tube (QTF-G-IT), enable detection of circulating T lymphocytes responsive to specific Mycobacterium tuberculosis antigens. Studies of the potential role of serial IGRAs for assessment of response to anti-tubercular therapy are accumulating.
Objective: The objective of this systematic review was to evaluate the potential clinical utility of serial IGRAs in anti-tubercular therapy.
Methods: We conducted a literature search of the Cochrane Library and MEDLINE by PubMed, from database inception through October 1, 2011, for serial IGRA results in anti-tubercular therapy, in adults and children, using commercial stardardized assays. All types of articles in the English language were included. Meta-analysis was performed to estimate the pooled percentage of reversion from a positive to a negative IGRA value at 3- to 6-month follow-up.
Results: According to inclusion and exclusion criteria, three T-SPOT.TB-based (n = 319 patients), three QFT-G-based (n = 75 patients), and seven QFT-G-IT-based (n = 558 patients) longitudinal studies were included. The percentage of patients with reversion from a positive to a negative IGRA value ranged from 5.71% to 13.93% for T-SPOT.TB, 5.26% to 71.05% for QFT-G, and 14.28% to 41.89% for QFT-G-IT assays. Meta-analysis estimation of reversion was feasible only for the QFT-G-IT assay, at 30.54% (95% CI, 22.89-38.75). In two pediatric studies, which were QFT-G-IT based (n = 122 children), the reported reversion rates were 14.28% and 20.33%, respectively.
Conclusions: Because IGRAs require time and cost resources, and reversion from positive to negative IGRA values occurs in a minority of treated patients, monitoring IGRA changes over time seems to have only speculative value in adults. Data in children are poor, but are in line with results reported in adults.
Chen K, Jiang F, Zhou Q, Dong X, He T, Li Y Ann Med. 2024; 55(2):2282182.
PMID: 38375813 PMC: 10812855. DOI: 10.1080/07853890.2023.2282182.
Du Y, Xin H, Cao X, Liu Z, He Y, Zhang B Front Microbiol. 2022; 13:934716.
PMID: 35935235 PMC: 9355536. DOI: 10.3389/fmicb.2022.934716.
Using TBAg/PHA Ratio for Monitoring TB Treatment: A Prospective Multicenter Study.
Wang X, Li M, Liu G, Wu X, Wan R, Hou H J Clin Med. 2022; 11(13).
PMID: 35807065 PMC: 9267548. DOI: 10.3390/jcm11133780.
Yang Y, Wang H, Hu W, Bai G, Hua C Diagnostics (Basel). 2022; 12(2).
PMID: 35204544 PMC: 8871457. DOI: 10.3390/diagnostics12020453.
Heterogenous Immune Response to TB is Not a False Negative.
Wang M, Liu X Am J Trop Med Hyg. 2020; 102(3):699.
PMID: 32519645 PMC: 7056440. DOI: 10.4269/ajtmh.19-0896b.